Pricing Log in Create free account

Akari Therapeutics PLC (AKTX) vs GT Biopharma, Inc. (GTBP)

Akari Therapeutics PLC and GT Biopharma, Inc. are both Biotechnology companies. Akari Therapeutics PLC and GT Biopharma, Inc. are of similar size ($15.5M and $15.2M). Across the 11 metrics below, Akari Therapeutics PLC leads on 6 and GT Biopharma, Inc. on 5.

Valuation

Metric AKTX GTBP Biotechnology median
P/E n/m n/m 8.50
P/S n/m 181.94 9.71
P/B 0.79 3.06 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 542.75 9.21
Earnings yield (316.31%) (2,098.15%) (33.15%)
Free cash flow yield (73.67%) (130.63%) (25.50%)

Profitability

Metric AKTX GTBP Biotechnology median
Gross margin 0.00% 41.67% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (140.09%) 102.03% (56.36%)
Return on assets (69.16%) (176.27%) (48.04%)
Return on invested capital (167.93%) 0.00% 0.00%

Growth

Metric AKTX GTBP Biotechnology median
Revenue growth (TTM) — (76.19%) 6.02%
EPS growth (last fiscal year) 68.99% 3.75% 30.26%
Revenue growth, 5-year CAGR — 19.67% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX GTBP Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 0.60 2.61 4.72
Net debt to EBITDA 0.27 0.56 0.96

Dividend

Metric AKTX GTBP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AKTX GTBP Biotechnology median
Market cap 15.47m 15.17m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack